chevron-down Created with Sketch Beta.
June 23, 2023

White House Meets with Pharma Companies: Pricing of Narcan

On June 20, White House officials met with ten  representatives from pharmaceutical companies to discuss the costs and accessibility of naloxone, one of the major overdose-reversal drugs on the market deemed “crucial to saving lives”. One major company, Emergent, is receiving stark criticism on their product to be released this summer, Narcan, which they plan to price at “less than $50”. Critics believe this cost is too high as a large population of users do not have insurance and will not be able to afford the lifesaving drug. Narcan was approved in March by the FDA to be sold over the counter, permitting access to all without a prescription, but there is no generic option currently available. 

The material in all ABA publications is copyrighted and may be reprinted by permission only. Request reprint permission here.